socalTECH
MAY 5, 2017
Leaf Group disclosed the sale in its first quarter 2017 results, where it reported a net loss of $10.0M Leaf Group said it paid $12.0M for Deny Designs, split between $6.7M in cash plus approximately 215,000 shares of its common stock. Deny Designs was based in Denver, Colorado. on revenues of $27.238M. READ MORE>>.
socalTECH
NOVEMBER 8, 2017
Venice, California-based Snap is set to see a punishing day on Wall Street, after reporting poorer than expected third quarter results last night, including poor user growth and sales. Shap continues to lose money, hand over first, reporting it had a net loss of $443.1M on Tuesday to around $13.33
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
DECEMBER 27, 2017
Speculation is rampant about a possible sea change in consumer attitudes toward the tech industry and its products—a shift that might affect sales, the regulatory environment, and other factors important to companies. We’ve just passed a year full of news about the role of technology companies in U.S.
InfoChachkie
MARCH 2, 2019
Ruth had previously headed the company’s sales efforts, but she formally moved up to the CEO role upon Matson’s departure. This is an especially remarkable feat, considering that America’s entire population at that time was 157 million, representing a sale to 1 out of every 1.7 In 1955, the company’s net work was $500,000 ($4.6
Xconomy
NOVEMBER 13, 2016
I widened my net this year. million in a Series D round of investment capital, according to founder and chairman Tony Farwell. The startups selected for this year’s list began, as it did last year, with a master list of companies screened by the San Diego Venture Group for its annual venture summit.
Xconomy
AUGUST 19, 2016
And once in a while, a defender uses his or her face, inadvertently, to block a ball spiked over the net. —The FDA last summer approved two new cholesterol fighting drugs known as PCSK9 inhibitors, but so far the market has rejected them, resulting in paltry sales. Talk about sacrifice.
Xconomy
AUGUST 26, 2016
The deal also includes a $175 million deferred payment due in 2019 and $850 million in downstream payouts tied to regulatory and sales targets. A Phase 2 trial of the drug, AMX0035, should start in late 2016 or early 2017. —Cambridge-based PixarBio is raising $30 million in a reverse merger with an undisclosed public entity.
Expert insights. Personalized for you.
113 
Let's personalize your content